Collaborative virtual screening to elaborate an imidazo[1,2- <i>a</i> ]pyridine hit series for visceral leishmaniasis
Yuichiro Akao(Fujisawa City Hospital), Benjamin Perry(Drugs for Neglected Diseases Initiative), Kazuya Nagaoka(Eisai (Japan)), Thierry Kogej(AstraZeneca (Singapore)), Sachiko Itono(Fujisawa City Hospital), Huanxu Xie(WuXi AppTec (China)), Naoaki Watanabe(Jikei University School of Medicine), Mitsuyuki Shimada(Fujisawa City Hospital), Rina Kaki(Toyonaka Municipal Hospital), Ola Engkvist(AstraZeneca (Australia)), Akira Naito(Wakamoto Pharmaceutical (Japan)), Ieuan O. Roberts(AstraZeneca (United Kingdom)), Kevin R. Condroski(Loxo Oncology at Lilly (United States)), Yafeng Cao(WuXi AppTec (China)), Garry Pairaudeau(AstraZeneca (United Kingdom)), Charles E. Mowbray(Drugs for Neglected Diseases Initiative), David Shum(Memorial Sloan Kettering Cancer Center), Osamu Yoshida(Ehime University Hospital), Ryu Yoshida(Toyonaka Municipal Hospital), Shuji Yonezawa(Toyonaka Municipal Hospital), C. Kimura(Toyonaka Municipal Hospital), Stacie Canan(Bristol-Myers Squibb (Switzerland)), Constantin Radu(Institut Pasteur Korea), Hiromi Nakai(Toyonaka Municipal Hospital)
Cited by 40
Related Papers
An analysis of the attrition of drug candidates from four major pharmaceutical companies
|Nature Reviews Drug Discovery|2015|1.4k
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Application of Generative Autoencoder in <i>De Novo</i> Molecular Design
|Molecular Informatics|2017|404
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388
Detection of urovirulence factors in<i>Escherichia coli</i>by multiplex polymerase chain reaction
|FEMS Immunology & Medical Microbiology|1995|317